Loading...
•
Jun 30, 2020
Cerus Q2 2020 Earnings Report
Cerus's Q2 2020 results were announced, featuring record quarterly product revenue and progress in development programs.
Key Takeaways
Cerus Corporation announced record second-quarter results, with total revenue reaching $26.8 million. Product revenue was $21.5 million, driven by strong platelet kit sales in the U.S. and plasma and illuminator sales in EMEA. The company reaffirmed its full-year product revenue guidance of $89 million to $93 million.
Total revenue reached $26.8 million, a 19.1% increase year-over-year.
Product revenue hit a record $21.5 million, driven by platelet kit sales in the U.S. and plasma and illuminator sales in EMEA.
Reaffirmed 2020 full-year product revenue guidance of $89 million to $93 million.
Submitted a pre-market approval supplement to the FDA for pathogen-reduced cryoprecipitated fibrinogen complex.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company expects 2020 product revenue to be in the range of $89 million to $93 million, unchanged from the guidance originally provided on January 13, 2020. The guidance range represents approximately 20% to 25% growth compared to 2019 reported product revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...